Other Articles by Author(s)

Xiaochuan Hu
Sophia R. J. Jang

Author(s) and WSEAS

Xiaochuan Hu
Sophia R. J. Jang

WSEAS Transactions on Biology and Biomedicine

Print ISSN: 1109-9518
E-ISSN: 2224-2902

Volume 15, 2018

Notice: As of 2014 and for the forthcoming years, the publication frequency/periodicity of WSEAS Journals is adapted to the 'continuously updated' model. What this means is that instead of being separated into issues, new papers will be added on a continuous basis, allowing a more regular flow and shorter publication times. The papers will appear in reverse order, therefore the most recent one will be on top.

Optimal Treatments in Cancer Immunotherapy Involving CD4+ T Cells

AUTHORS: Xiaochuan Hu, Sophia R. J. Jang

Download as PDF

ABSTRACT: We apply optimal control theory to a model of interactions between cancer cells, CD4+ T cells, cytokines and host cells to devise best immunotherapies for treating cancer. The CD4+ T cells cannot kill cancer cells directly but use the cytokines produced to suppress tumor growth. The immunotherapy implemented is modeled as a control agent and it can be either transferring of CD4+ T cells, cytokines or both. We establish existence and uniqueness of the optimal control. The optimal treatment strategy is then solved numerically under different scenarios. Our numerical results provide best protocols in terms of strengths and timing of the treatments.

KEYWORDS: Cytokine, Immunotherapy, Ordinary Differential equations, Optimal Control, Tumor


[1] R.A. Weinberg, The Biology of Cancer, 2nd ed., Garland Science: London, UK, 2013.

[2] R. Eftimie et al., Interaction between the immune system and cancer: a brief review of non-spatial mathematical models, Bull. Math. Biol., vol. 73, 2011, pp. 2-32.

[3] J. Mattes et al., Immunotherapy of cytotoxic T cellresistant tumors by T helper 2 cells: An eotaxin and STAT6-dependent process, J. Exp. Med., vol. 197, 2003, pp. 387-393.

[4] A. Corthay, D.K. Skovseth, K.U. Lundin, et al., Primary antitumor immune response mediated by CD4+ T cells, Immunity, vol. 22, 2005, pp. 371-383.

[5] E. Fernandez-Cruz, B.A. Woda, J.D. Feldman, Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes, J. Exp. Med., vol. 152, 1980, pp. 823-841. 13

[6] P.D. Greenberg, D.E. Kern, M.A. Cheever, Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells, J. Exp. Med., vol. 161, 1985, pp. 1122-1134.

[7] D. Mumberg. P.A. Monach, S. Wanderling, CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma, Proc. Natl. Acad. Sci. USA, vol. 96, 1999, pp. 8633-8638.

[8] Z. Qin, T. Blankenstein, CD4+ T cellmediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells, Immunity, vol. 12, 2000, pp. 677-686.

[9] A. Perez-Diez et al., CD4 cells can be more efficient at tumor rejection than CD8 cells, Blood, vol. 109, 2007, pp. 5346-5354.

[10] S. Zhang, CD4 T-cell-mediated anti-tumor immunity can be uncoupled from autoimmunity via the STAT4/STAT6 signaling axis, Eur. J. Immunol., vol. 39, 2009, pp. 1252-1259.

[11] L. de Pillis et al., A validated mathematical model of cell-mediated immune response to tumor growth, Cancer Res., vol. 65, 2005, pp. 7950-7958.

[12] B. Goldstein, J. Faeder, W. Hlavacek, Mathematical and computational models of immunereceptor signaling, Nat. Rev. Immunol., vol. 4, 2004, pp. 445-456.

[13] N. Kronik et al., Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics, Cancer Immunol. Immunother., vol. 57, 2008, pp. 425-439.

[14] N. Kronik et al., Improving T-cell immunotherapy for melanoma through a mathematicall motivated strategy: efficacy in numbers?, J. Immmunother., vol. 35, 2012, pp. 116-124.

[15] U. Forys et al., Anti-tumor immunity and tumor anti-immunity in a mathematical model of tumor immunotherapy, J. Biol. Syst., vol. 14, 2006, pp. 13-30.

[16] V. Kuznetsov et al., 1994. Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis, Bull. Math. Biol., vol. 2, 1994, pp. 295-321.

[17] S. Michelson et al., Tumor micro-ecology and competitive interactions, J. Theor. Biol., vol. 128, 1987, pp. 233-246.

[18] H. de Vladar, J. Gonzlez, Dynamic response of cancer under the influence of immunological activity and therapy, J. Theor. Biol., vol. 227, 2004, pp. 335-348.

[19] D. Kirschner, J.C. Panetta, Modeling immunotherapy of the tumor immune interaction, J. Math. Biol., vol. 37, 1998, pp. 235-252.

[20] R. Eftimie et al., Anti-tumour Th1 and Th2 immunity in the rejection of melanoma, J. Theor. Biol., vol. 265, 2010, pp. 467-480.

[21] L. Anderson, S. R-J. Jang, J. Yu, Qualitative behavior of systems of tumor-CD4+-cytokine interactions with treatments, Math. Meth. Appl. Sci., vol. 38, 2015, pp. 4330-4344. 14

[22] D. Hanahan, R. Weinberg, Hallmarks of cancer, Cell, vol. 100, 2010, pp. 57-70.

[23] X. Hu, S. R-J. Jang, Dynamics of tumor-CD4+-cytokine-host cells interactions with treatments, App. Math. Comput., vol. 321, 2018, pp. 700-720.

[24] T. Burden, J. Ernstberger, K. Fister, Optimal control applied to immunotherapy, Dis. Cont. Dyn. Sys. Ser. B, vol. 4, 2004, pp. 135-146.

[25] F. Castiglione, B. Piccoli, Cancer immunotherapy, mathematical modeling and optimal control, J. Theor. Biol., vol. 247, 2007, pp. 723-732.

[26] S. Khajanchi, D. Ghosh, The combined effects of optimal control in cancer remission, Appl. Math. Compu., vol. 271, 2015, pp. 375-388.

[27] A. Minelli, F. Topputo, F. Bernelli-Zazzera, Controlled drug deliver in cancer immunotherapy: stability, optimization, and Monte Carlo analysis, SIAM J. Appl. Math., vol. 71, 2011, pp. 2220-2245.

[28] S. Sharma, G.P. Samanta, Analysis of the dynamics of a tumor-immune system with chemotherapy and immunotherapy and quadratic optimal control, Differ. Equ. Dyn. Sys., vol.24, 2016, pp. 149-171.

[29] A. Lopez, J. Seoane, M. Sanjuan, A validated mathematical model of tumor growth including tumorhost interaction, cell-mediated immune response and chemotherapy, Bull. Math. Biol., vol. 76, 2014, pp. 2884-2906.

[30] M. Engelhart, D. Lebiedz, D. Sager, Optimal control for selected cancer chemotherapy ODE models: A view on the potential of optimal schedules and choice of objective function, Math. Biosci., vol. 229, 2011, pp. 123-134.

[31] W. Fleming, R. Rishel, Deterministic and Stochastic Optimal Control, Springer: New York, 1975.

[32] L. Lenhart, JT. Workman, Optimal Control Applied to Biological Models, Chapman & Hall: NewYork, 2007.

[33] F. Fister, S. Lenhart, J. McNally, Optimizing chemotherapy in an HIV model, Elec. J. Diff. Equ., vol. 32, 1998, pp. 1-12.

[34] J. Arciero, T. Jackson, D. Kirschner, A mathematical model of tumor- immune evasion and siRNA treatment, Dis. Con. Dyn.Sys. Ser. B, vol. 4, 2004, pp. 39-58.

[35] H,R. Thieme, Mathematics in Population Biology, Princeton University Press: New Jersey, 2003

WSEAS Transactions on Biology and Biomedicine, ISSN / E-ISSN: 1109-9518 / 2224-2902, Volume 15, 2018, Art. #7, pp. 48-67

Copyright © 2018 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution License 4.0

Bulletin Board


The editorial board is accepting papers.

WSEAS Main Site